Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: A prospective observational study

Vaccine

Volumn 22, Issue 15-16, 2004, Pages 2006-2012

  Hung, Chien Ching ^a,b   Chen, Mao Yuan ^a   Hsieh, Szu Min ^a   Hsiao, Chin Fu ^c   Sheng, Wang Hwei ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

AIDS; Highly active antiretroviral therapy; HIV 1 infection; Pneumococcal vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; MACROLIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; RIFAMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; CELL COUNT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; FEMALE; HAZARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TAIWAN; VACCINATION; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 2342597188     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.030     Document Type: Article

References (17)

1. Redd S.C., Rutherford G.W. III, Sande M.A., et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J. Infect. Dis. 162:1990;1012-1017
2. Centers for Disease control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-25.
3. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2002 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 2002;51:1-64.
4. Gebo K.A., Moore R.D., Keruly J.C., Chaisson R.E. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:1996;857-862
5. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet. 355:2000;2106-2111
6. Breiman R.F., Keller D.W., Phelan M.A., Sniadack D.H., Stephens D.S., Rimland D., et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Intern. Med. 160:2000;2633-2638
7. Dworkin M.S., Ward J.W., Hanson D.L., Jones J.L., Kaplan J.E. the Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin. Infect. Dis. 32:2001;794-800
8. Hung C.C., Chen M.Y., Hsieh S.M., Sheng W.H., Chang S.C. Clinical spectrum, morbidity and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. J. Acquir. Immune. Defic. Syndr. 24:2000;378-385
9. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
10. Brichacek B., Swindells S., Janoff E.N., Pirruccello S., Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174:1996;1191-1199
11. Fine M.J., Smith M.A., Carson C.A., et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 154:1994;2666-2677
12. Rodriguez-Barradas M.C., Musher D.M., Lahart C., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J. Infect. Dis. 165:1992;553-556
13. Janoff E.N., O'Brien J., Thompson P., et al. Streptococcus pneumoniae colonization, bacteremia, and immune response among patients with human immunodeficiency virus infection. J. Infect. Dis. 167:1993;49-56
14. Carson P.J., Schut R.L., Simpson M.L., O'brien J., Janoff E.N. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J. Infect. Dis. 172:1995;340-345
15. Glaser J.B., Volpe S., Aguirre A., Simpkins H., Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J. Infect. Dis. 164:1991;761-764
16. Nuroti J.P., Butler J.C., Gelling L., Kool J.L., Reingold A.L., Vugia D.J. Epidemiologic relationship between HIV and invasive pneumococcal disease in San Francisco County, California. Ann. Intern. Med. 132:2000;182-190
17. Palella F.J.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N. Engl. J. Med. 338:1998;853-860